Merck & Co (MRK) said Thursday that new data from a phase 3 trial of Enflonsia in infants and children at increased risk for severe respiratory syncytial virus disease showed a safety profile consistent with that observed in the first season of the study.

The company said the findings reinforce the drug's potential as a preventive option for vulnerable pediatric populations.

Merck plans to submit the second season data set to the US Food and Drug Administration.

The drug is currently approved for use in the US, Canada and other countries.